$VKTX News

Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years

Viking Therapeutics: Still Cheap, But Watch Double Top

Viking Advances New Amylin-Based Weight-Loss Drug Into Human Trials

Viking Therapeutics Initiates Phase 1 Ascending Dose Trial Of VK3019, An Investigational Dual Amylin And Calcitonin Receptor Agonist For Weight Loss; Data Expected In 3Q26

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Lake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89

Viking Therapeutics Presents Additional Data From Phase 2 VENTURE-Oral Dosing Trial Evaluating Oral Tablet Formulation Of VK2735 At ECO In Istanbul, Türkiye

Cantor Fitzgerald Maintains Overweight on Viking Therapeutics, Lowers Price Target to $100

Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard

Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript

Viking Therapeutics (NASDAQ:VKTX) Stock Holds Steady After Q1 2026 Earnings Miss on Higher Phase 3 Spending

Viking Therapeutics Q1 EPS $(1.37) Misses $(1.02) Estimate

Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts

Did VK2735’s VANQUISH-2 Enrollment Milestone Just Reframe Viking Therapeutics' (VKTX) Obesity Drug Ambitions?

Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today

Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors

Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution

A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Phase 3 Enrollment Reaches Completion

Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735